ABCL vs CB · rev $28.8M vs P/E 14, rev $59.40B
Abcellera Biologics Inc (ABCL) versus Chubb Ltd (CB) — a side-by-side from cached financials, not a winner call.
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
Chubb Ltd (CB) is a insurance - property & casualty company listed on US.
Latest reported ABCL revenue for 2024-12-31 was $28.8M. Net income was -$162.9M. Revenue was down 24.2% from 2023-12-31 to 2024-12-31. ABCL currently screens at market cap $1.12B.
Latest reported CB revenue for 2025-12-31 was $59.40B. Net income was $10.31B. Revenue was up 6.5% from 2024-12-31 to 2025-12-31. CB currently screens at market cap $114.26B and trailing P/E 13.7.
ABCL currently screens at market cap $1.12B. CB currently screens at market cap $114.26B and trailing P/E 13.7.
Not investment advice. Open the ABCL and CB stock pages for the full models.
Not investment advice.